Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)

Volker Kunzmann; Uwe Marc Martens; Hana Alguel; Jens T. Siveke; Eray Goekkurt; Uwe Pelzer; Gabriele Margareta Siegler; Elke Hennes; Dirk Waldschmidt; Ralf Jakobs; Peter Ferenczy; Ralph Keller; Stefan Hubert Boeck; Frank Kullmann; Markus Kapp; Christoph Thomas Germer

doi:10.1200/JCO.2018.36.4_SUPPL.348

Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)

Volker Kunzmann, Uwe Marc Martens, Hana Alguel, Jens T. Siveke, Eray Goekkurt, Uwe Pelzer, Gabriele Margareta Siegler, Elke Hennes, Dirk Waldschmidt, Ralf Jakobs, Peter Ferenczy, Ralph Keller, Stefan Hubert Boeck, Frank Kullmann, Markus Kapp, Christoph Thomas Germer

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

3 Citations (Web of Science)

Original language	Undefined/Unknown
Journal	Journal of Clinical Oncology
DOIs	https://doi.org/10.1200/JCO.2018.36.4_SUPPL.348
Publication status	Published - 2018

Access to Document

10.1200/JCO.2018.36.4_SUPPL.348

Cite this

Kunzmann, V., Martens, U. M., Alguel, H., Siveke, J. T., Goekkurt, E., Pelzer, U., Siegler, G. M., Hennes, E., Waldschmidt, D., Jakobs, R., Ferenczy, P., Keller, R., Boeck, S. H., Kullmann, F., Kapp, M., & Germer, C. T. (2018). Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP). Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2018.36.4_SUPPL.348

@article{3fb9ae7d59e34b7d9f36f8b4866439d0,

title = "Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)",

author = "Volker Kunzmann and Martens, {Uwe Marc} and Hana Alguel and Siveke, {Jens T.} and Eray Goekkurt and Uwe Pelzer and Siegler, {Gabriele Margareta} and Elke Hennes and Dirk Waldschmidt and Ralf Jakobs and Peter Ferenczy and Ralph Keller and Boeck, {Stefan Hubert} and Frank Kullmann and Markus Kapp and Germer, {Christoph Thomas}",

year = "2018",

doi = "10.1200/JCO.2018.36.4_SUPPL.348",

language = "Undefined/Unknown",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

}

Kunzmann, V, Martens, UM, Alguel, H, Siveke, JT, Goekkurt, E, Pelzer, U, Siegler, GM, Hennes, E, Waldschmidt, D, Jakobs, R, Ferenczy, P, Keller, R, Boeck, SH, Kullmann, F, Kapp, M & Germer, CT 2018, 'Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)', Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2018.36.4_SUPPL.348

Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP). / Kunzmann, Volker; Martens, Uwe Marc; Alguel, Hana et al.
In: Journal of Clinical Oncology, 2018.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)

AU - Kunzmann, Volker

AU - Martens, Uwe Marc

AU - Alguel, Hana

AU - Siveke, Jens T.

AU - Goekkurt, Eray

AU - Pelzer, Uwe

AU - Siegler, Gabriele Margareta

AU - Hennes, Elke

AU - Waldschmidt, Dirk

AU - Jakobs, Ralf

AU - Ferenczy, Peter

AU - Keller, Ralph

AU - Boeck, Stefan Hubert

AU - Kullmann, Frank

AU - Kapp, Markus

AU - Germer, Christoph Thomas

PY - 2018

Y1 - 2018

UR - https://publons.com/wos-op/publon/27618472/

U2 - 10.1200/JCO.2018.36.4_SUPPL.348

DO - 10.1200/JCO.2018.36.4_SUPPL.348

M3 - Originalarbeit

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP)

Access to Document

Other files and links

Cite this